coronaviru
infect
associ
sever
diseas
lower
respiratori
gastrointestin
tract
human
anim
yet
littl
known
underli
molecular
mechan
govern
virul
pathogenesi
among
human
coronavirus
etiolog
agent
sar
sar
coronaviru
sarscov
attract
model
studi
molecular
basi
pathogenesi
given
robust
vitro
growth
characterist
avail
revers
genet
system
anim
model
wealth
clinic
data
sever
solv
replicas
accessori
protein
structur
sar
cov
infect
afflict
human
result
death
worldwid
diseas
sever
link
age
approxim
mortal
rate
year
age
age
age
mani
survivor
suffer
longlast
lung
cardiac
complic
underli
mechan
govern
sarscov
pathogenesi
unravel
sarscov
zoonot
pathogen
cross
speci
barrier
like
host
civet
cat
raccoon
dog
although
viru
also
isol
detect
domest
cat
swine
rodent
aggress
public
health
effort
contain
epidem
unclear
whether
epidem
strain
extinct
wild
given
signific
health
econom
impact
sarscov
outbreak
effect
vaccin
strategi
sar
includ
protect
epidem
zoontoic
strain
viru
risk
elderli
popul
vulner
sever
diseas
essenti
phylogenet
analys
suggest
sarscov
either
repres
prototyp
group
iv
coronaviru
studi
place
viru
earli
splitoff
group
ii
molecular
evolutionari
studi
isol
obtain
differ
stage
outbreak
implic
chang
glycoprotein
variou
accessori
orf
associ
increas
virul
transmiss
pathogenesi
epidem
sarscov
virion
contain
singlestrand
posit
polar
nucleotid
rna
genom
bound
nucleocapsid
protein
n
capsid
surround
lipid
bilay
contain
least
three
structur
protein
design
e
protein
like
essenti
effici
virion
matur
releas
sarscov
protein
requir
subgenom
genom
length
rna
synthesi
viru
replic
orf
encod
eight
subgenom
mrna
synthes
nest
set
cotermin
molecul
leader
rna
sequenc
encod
end
genom
join
bodi
sequenc
distinct
transcript
regulatori
sequenc
contain
highli
conserv
consensu
sequenc
develop
sarscov
molecular
clone
provid
use
tool
develop
novel
sarscov
isol
identifi
genet
determin
respons
increas
pathogenesi
epidem
develop
zoonot
strain
vaccin
test
epidem
urbani
strain
sarscov
molecularli
deriv
recombin
viru
icsarscov
use
throughout
studi
glycoprotein
synthet
reconstruct
publish
sequenc
insert
molecular
clone
sarscov
use
isol
recombin
viru
encod
glycoprotein
urbani
glycoprotein
nucleocapsid
gene
insert
venezuelan
equin
enceph
viru
replicon
particl
vrp
use
method
describ
literatur
vrp
vaccin
result
phylogenet
analysi
sarscov
isol
anim
human
make
compel
argument
viru
origin
anim
like
palm
civet
raccoon
dog
transmit
human
popul
via
live
anim
market
howev
actual
reservoir
sarscov
clearli
determin
although
recent
unpublish
report
china
suggest
possibl
origin
bat
use
bayesian
method
sequenc
anim
human
sarscov
isol
note
sarscov
isol
divid
genoclust
includ
anim
isol
like
gi
cluster
isol
associ
sporad
mild
human
anim
addit
glycoprotein
e
spike
glycoprotein
interact
receptor
angiotensin
ii
convert
enzym
mediat
entri
cell
genom
contain
princip
orf
encod
viral
replicas
stock
titer
x
use
vaccin
wildtyp
icsarscov
sever
week
month
later
neutral
titer
determin
treat
plaqu
icsarscov
vari
concentr
serum
human
anim
measur
reduct
infect
vero
cell
monolay
x
vrp
twentyeight
day
later
anim
boost
footpad
innocul
challeng
infect
gii
cluster
highli
pathogen
strain
associ
earli
middl
late
phase
isol
epidem
giii
figur
gener
gii
isol
usual
isol
anim
although
rare
mild
case
infect
human
report
gi
isol
detect
anim
glycoprotein
sequenc
obtain
sporad
mild
human
case
report
dec
viru
never
success
cultur
vitro
divers
human
isol
detail
map
studi
indic
least
three
neutral
epitop
resid
within
urbani
glycoprotein
monoclon
antibodi
bind
site
b
possess
signific
neutral
activ
wildtyp
virus
complet
protect
anim
infect
site
b
overlap
receptor
bind
site
known
interact
site
c
repres
time
less
robust
neutral
site
presum
antibodi
interfer
viru
dock
entri
mechan
depend
upon
function
heptad
repeat
encod
cterminu
variat
sarscov
glycoprotein
report
although
detail
cross
neutral
studi
cross
protect
studi
anim
model
compar
suscept
epidem
experiment
vaccin
develop
test
anim
model
primarili
rodent
murin
model
princip
compon
protect
immun
neutral
antiserum
direct
sar
glycoprotein
passiv
transfer
neutral
antibodi
suffici
protect
viru
replic
surprisingli
kill
recombin
viru
vaccin
elicit
neutral
antibodi
protect
mice
sarscov
replic
lung
importantli
advers
reaction
note
ferret
vaccin
recombin
poxvirus
encod
sarscov
glycoprotein
includ
lack
protect
heterolog
glycoprotein
neutral
evalu
extens
variat
note
isol
group
ii
isol
raccoon
dog
civet
amino
acid
sequenc
variat
glycoprotein
report
compar
urbani
epidem
strain
glycoprotein
contain
variat
within
neutral
site
although
less
clear
whether
heterogen
alter
neutral
kinet
associ
antiserum
gener
epidem
strain
infect
increas
hepat
patholog
vaccin
anim
molecular
basi
increas
patholog
vaccin
anim
remain
unknown
import
unresolv
question
remain
regard
develop
efficaci
popul
vaccin
efficaci
vulner
senesc
anim
model
sarscov
infect
evalu
abil
vaccin
induc
robust
immun
elicit
elderli
popul
senesc
immun
system
longterm
shortterm
genoclust
languish
due
lack
heterolog
isol
final
molecular
mechan
govern
vaccin
mediat
immunopathogenesi
enhanc
diseas
ferret
must
elucid
mani
anim
earli
human
isol
sequenc
never
success
cultur
vitro
address
problem
systemat
approach
involv
molecular
clone
sarscov
synthet
biolog
use
success
resurrect
earli
sarscov
vaccin
sever
diseas
high
death
rate
note
elderli
human
respons
age
popul
evalu
determin
protect
human
anim
isol
figur
detail
resurrect
glycoprotein
gene
urbani
molecular
clone
discuss
detail
articl
sheahan
et
al
chapter
viru
replic
high
titer
vero
cell
mice
resist
neutral
antiserum
monoclon
immun
wane
immun
cross
protect
strain
differ
evalu
vaccin
efficaci
homolog
heterolog
strain
urbani
glycoprotein
nucleocapsid
gene
clone
insert
venezuelan
equin
enceph
viru
replicon
particl
vrp
vrpn
use
standard
approach
report
laboratori
previous
addit
influenza
ha
glycoprotein
vrpha
use
control
vector
balbc
mice
vaccin
x
infecti
unit
vrpsha
combin
vrp
svrpn
boost
week
later
challeng
icsarscov
week
postboost
tabl
age
senesc
mice
exceed
year
time
challeng
importantli
vrp
vaccin
provid
complet
shortterm
protect
homolog
heterolog
isol
vrp
svrpn
vaccin
anim
protect
challeng
vrp
vaccin
also
provid
longterm
protect
homolog
challeng
protect
senesc
mice
icsarscov
replic
although
age
mice
vaccin
vrpha
demonstr
patholog
lesion
lung
similar
report
literatur
vrp
svrpn
vaccin
mice
display
littl
patholog
lesion
lung
data
shown
contrast
vrpsvrpn
vaccin
mice
provid
littl
longterm
protect
infect
although
viru
titer
reduc
compar
vrpha
control
challeng
viru
also
produc
patholog
lesion
vrpha
sar
vaccin
anim
virtual
indistinguish
icsarscov
infect
data
shown
time
like
rapid
wane
immun
heterolog
challeng
virus
result
vaccin
failur
age
anim
antibodi
direct
urbani
strain
sarscov
tabl
consist
note
sequenc
variat
domain
recogn
neutral
antibodi
sarscov
zoonot
pathogen
sever
case
like
anim
human
transmiss
report
china
case
infect
mild
spread
beyond
index
case
suggest
anim
virus
requir
addit
adapt
prior
evolv
effici
usag
human
host
adapt
human
host
sever
diseas
manifest
occur
within
elderli
popul
like
compromis
wane
innat
immun
acquir
immun
respons
pathogen
insult
importantli
sever
zoonot
strain
genoclust
ii
close
relat
display
heterogen
neutral
epitop
site
encod
determin
glycoprotein
gene
consist
rapid
human
adapt
spread
data
suggest
current
vaccin
formul
test
epidem
strain
also
evalu
protect
therapeut
potenti
zoonot
reintroduct
address
need
resurrect
live
sarscov
encod
glycoprotein
demonstr
viru
replic
effici
vitro
vivo
produc
patholog
lesion
age
mice
shown
polioviru
influenza
viru
gene
data
provid
addit
support
use
synthet
dna
revers
genet
mean
rescu
extinct
virus
viral
gene
improv
vaccin
enhanc
overal
public
health
icsarscov
recombin
viru
demonstr
gap
vaccin
design
control
futur
sarscov
epidem
result
consist
earlier
report
suggest
zoonot
virus
highli
resist
neutral
antiserum
direct
epidem
strain
like
urbani
importantli
vrp
vaccin
elicit
high
level
neutral
antiserum
homolog
isol
less
effici
neutral
respons
recombin
viru
high
neutral
respons
like
translat
effici
protect
homolog
infect
young
age
mice
also
provid
shortterm
protect
homolog
protect
younger
anim
age
anim
respons
wane
elderli
immun
system
deterior
suffici
allow
robust
replic
pathogenesi
like
vaccin
approach
induc
less
robust
neutral
respons
like
dna
kill
vaccin
might
complet
fail
protect
challeng
rectifi
problem
booster
vaccin
consid
senesc
popul
new
vaccin
formul
assembl
includ
glycoprotein
determin
protect
epidem
zoonot
form
sarscov
futur
studi
evalu
singl
vrp
regiment
includ
either
vrp
vrpn
candid
vaccin
separ
approach
may
enhanc
overal
protect
vrp
vaccin
anim
clearli
avail
sarscov
strain
harbor
zoonot
glycoprotein
provid
import
futur
refer
inoculum
evalu
robust
new
vaccin
candid
anim
grow
recognit
human
coronavirus
produc
signific
pulmonari
diseas
human
place
sarscov
excel
posit
serv
premier
model
system
elucid
molecular
mechan
govern
human
coronaviru
pathogenesi
lung
identifi
compon
protect
immun
prevent
sever
lower
respiratori
tract
infect
human
anim
current
anim
model
sarscov
usual
display
littl
clinic
diseas
rare
caus
death
hamper
measur
vaccin
efficaci
sever
infect
diseas
anim
model
mirror
immunopatholog
pathophysiolog
chang
note
human
need
futur
vaccin
test
